A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in patients with rheumatoid arthritis

Inclusion Criteria:

• Completion of a previous D2E7 study
• Subject is in good health (Investigator discretion) with a recent stable medical history

Exclusion Criteria:

• Former enrollment in this trial (DE018)
• Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
• Female subject who is pregnant or breast feeding or considering becoming pregnant.